| Identification | More | [Name]
FLAVOXATE | [CAS]
15301-69-6 | [Synonyms]
FLAVOXATE
2-(1-Piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate
2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate
4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinyl)ethyl ester
3-Methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylic acid 2-piperidinoethyl ester | [EINECS(EC#)]
239-337-5 | [Molecular Formula]
C24H25NO4 | [MDL Number]
MFCD00210291 | [Molecular Weight]
391.46 | [MOL File]
15301-69-6.mol |
| Chemical Properties | Back Directory | [Melting point ]
87-88 °C | [Boiling point ]
564.1±50.0 °C(Predicted) | [density ]
1.203±0.06 g/cm3(Predicted) | [form ]
Off-white solid. | [pka]
7.3(at 25℃) | [InChI]
InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3 | [InChIKey]
SPIUTQOUKAMGCX-UHFFFAOYSA-N | [SMILES]
C1(C2=CC=CC=C2)OC2=C(C(OCCN3CCCCC3)=O)C=CC=C2C(=O)C=1C | [CAS DataBase Reference]
15301-69-6(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Originator]
Urispas,SKF,US,1971 | [Uses]
Flavoxate is a pharmaceutical active-containing film delivery device for oral transmucosal administration. | [Uses]
Relaxant (smooth muscle). | [Definition]
ChEBI: A carboxylic ester resulting from the formal condensation of 3-methylflavone-8-carboxylic acid with 2-(1-piperidinyl)ethanol. | [Manufacturing Process]
A mixture of 13.3 grams of anhydrous aluminum chloride and 100 ml of
carbon disulfide is added to 19.4 grams of 2-propionyloxybenzoic acid
(prepared from the reaction of propionyl chloride and 2-hydroxybenzoic acid).
After an initial evolution of hydrogen chloride, the solvent is removed by
distillation and the mixture is heated at 150° to 160°C for 4 hours. The cooled
reaction mixture is treated with ice and hydrochloric acid and the product, 2-
hydroxy-3-carboxypropiophenone, is obtained from the oily residue by
distillation in vacuo.
A mixture of 1.9 grams of 2-hydroxy-3-carboxypropiophenone, 5.0 grams of
sodium benzoate and 20.0 grams of benzoic anhydride is heated at 180° to
190°C for 6 hours. A solution of 15.0 grams of potassium hydroxide in 50 ml
of ethanol and 20 ml of water is added and refluxed for 1 hour. The mixture is
evaporated and the residue after addition of water yields 3-methylflavone-8-
carboxylic acid.
To a suspension of 12.0 grams of 3-methylflavone-8-carboxylic acid in 200 ml
of anhydrous benzene is added 10.0 grams of thionyl chloride. The mixture is
refluxed for 2 hours during which the suspended solid goes into solution. The
solvent is completely removed by distillation, the residue extracted with
benzene and the extract evaporated to dryness. The product, 3-
methylflavone-8-carboxylic acid chloride, is recrystallized from ligroin to give
crystals melting at 155° to 156°C.
To 11.0 grams of 3-methylflavone-8-carboxylic acid chloride dissolved in 150
ml of anhydrous benzene is added at room temperature 4.8 grams of
piperidinoethanol and the mixture refluxed for 2 to 3 hours. The separated
solid is filtered, washed with benzene and dried. The product, piperidinoethyl
3-methylflavone-8-carboxylate hydrochloride is obtained as a colorless
crystalline solid, MP 232° to 234°C, (from US Patent 2,921,070). | [Brand name]
Urispas (Ortho-McNeil). | [Therapeutic Function]
Spasmolytic |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
| Company Name: |
HBCChem, Inc.
|
| Tel: |
+1-510-219-6317 |
| Website: |
www.warehouse-sample-usa.com |
|